Navigation Links
Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Date:10/6/2008

expert in translational medicine, and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. The Lieberman laboratory at Harvard was the first to demonstrate that RNAi could be used to treat disease in an animal model. Dr. Lieberman and her colleagues are currently working to harness RNAi for use against HIV and other viruses and they have developed novel strategies for cell-specific targeting of small interfering RNAs to confer in vivo protection from viral disease. In related work, Dr. Lieberman's laboratory is also working in the emerging field of miRNAs by developing their potential as diagnostic and therapeutic tools.

Professor Patrice Courvalin, M.D., is head of the Antibacterial Agents Unit at the Institut Pasteur, Paris, France, where he directs the French National Reference Center for Antibiotics. He is an internationally recognized expert in the genetics and biochemistry of antibiotic resistance and in the transfer and heterologous expression of genetic information. He received master's degrees in sciences and in human biology from the University of Sciences in Paris and his doctorate in medical sciences from the Medical School in Paris. His research has led to a revision of the dogma describing natural dissemination of genes. In particular, he and his colleagues demonstrated that a wide variety of bacteria can promiscuously exchange genetic material and they proved that conjugation could account for dissemination of genes between phylogenetically remote bacterial genera. Because of his long-term interest in horizontal gene transfer among bacteria, Dr. Courvalin has been a thought leader in the area of using bacteria as intracellular vectors for delivery of DNA or proteins into mammalian cells. His laboratory was the first to describe the combination of invasin and listeriolysin to enable Escherichia coli as a gene therapy tool.

About Cequent Pharmaceuticals, Inc.

SOURCE Cequent Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
7. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Thermo Fisher Scientific to Present at Investor Conferences
10. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
11. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Pharma, Inc.,(Nasdaq: IDMI ), a biotechnology company focused ... Timothy P. Walbert,president and chief executive officer, will present ... Diego on Thursday, November 1, 2007,at 2 p.m. PDT ... webcast of the presentation will be available live and ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) has announced the ... Financial and Accounting Officer.,Immunosyn,s former Chief Financial and ... as the company,s Chairman of the Board and,further ... believe that the platform technology and its resulting,biopharmaceutical ...
... Md., Oct. 29 /PRNewswire/,-- Cambridge Antibody Technology ... to,reflect AstraZeneca,s vision for its worldwide biologics ... resources and expertise from CAT, the pre-,existing ... AstraZeneca,Group, under the "MedImmune" name. With this ...
Cached Biology Technology:IDM Pharma to Present at BIOCOM Investor Conference 2IDM Pharma to Present at BIOCOM Investor Conference 3Immunosyn Corporation Names G. David Criner as CFO 2AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune 2
(Date:9/2/2014)... study published in the September 2014 issue of ... Child and Adolescent Psychiatry found that children ... an increased risk of developing diabetes if they ... the nationwide Danish registers, a group of researchers ... University Hospital, Denmark, studied 48,299children and adolescents with ...
(Date:9/2/2014)... N.C. -- When you accidentally touch a hot oven, ... the basic neural circuits involved in sensing and responding ... the molecular players. , Duke researchers have made a ... involved in pain in worms, and have built a ... 2 in Nature Communications , may help direct ...
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Nature's tiny engineers 2Nature's tiny engineers 3
... Jan. 7, 2014 DigitalPersona, Inc., a trusted ... that its TouchChip® TCS1 sensor is the only ... the Ministry of Public Security under general technical ... for the China Resident Identity Card.  Miaxis Biometrics ...
... FL (January 6, 2014) Of the 1.9 million species ... 1.3 million are invertebrates. They have served as model organisms ... of the important role of invertebrates in science including sea ... and Loligo for neurobiology research, the fruit fly ...
... 2014) Autism Speaks, the world,s leading autism science ... $2.7 million for the funding of 13 new research ... address Autism Speaks, Early Access to Care initiative to ... to high-quality early intervention for all children affected by ...
Cached Biology News:Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 2Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 3New organization brings together top researchers to sequence the genomes of invertebrates 2New organization brings together top researchers to sequence the genomes of invertebrates 3Autism Speaks awards nearly $2.7 million for new research projects 2Autism Speaks awards nearly $2.7 million for new research projects 3Autism Speaks awards nearly $2.7 million for new research projects 4
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: